Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter on 'Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated MASH Cirrhosis for Fibrosis Regression and MASH Resolution'. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Longitudinal Validation of Clinical Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease in a Prospective Cohort of Individuals With Type 2 Diabetes.

Gastro hep advances·2026
Same author

Letter: Beyond Feasibility-The Need for Longer Duration and Composite NIT Endpoints in Biopsy-Free MASH Trials: Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States.

Journal of viral hepatitis·2026
Same author

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.

Alimentary pharmacology & therapeutics·2026
Same author

Clinical Use of Noninvasive Testing for Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Jun 24, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS

Maria Mironova1, Kaleb Tesfai1, Egbert Madamba1

  • 1MASLD Research Center, Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, 92037.

The American Journal of Gastroenterology
|June 23, 2026
PubMed
Summary
This summary is machine-generated.

Overweight individuals with any cardiometabolic risk factor, not just diabetes, should be screened for metabolic dysfunction-associated steatotic liver disease (MASLD). This broader screening identifies more cases of MASLD and advanced liver fibrosis in at-risk populations.

Keywords:
cirrhosisfatty livernon-invasive assessmentobesityprimary caresteatosis

Related Experiment Videos

Last Updated: Jun 24, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Area of Science:

  • Hepatology
  • Metabolic Syndrome
  • Liver Disease Screening

Background:

  • Current guidelines recommend fibrosis evaluation in diabetes and screening for MASLD in individuals with cardiometabolic risk factors (CMRFs).
  • However, guidelines lack specificity regarding which risk factors warrant screening in overweight individuals.
  • This study aimed to identify specific risk factors prompting liver disease assessment in overweight populations.

Purpose of the Study:

  • To identify key risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced fibrosis in overweight adults.
  • To inform expanded screening recommendations for liver disease in overweight individuals.

Main Methods:

  • Cross-sectional analysis of 220 overweight adults (aged 40-75) from a prospective study in Southern California.
  • MASLD defined as liver fat content ≥5% by MRI-PDFF; advanced fibrosis defined as ≥3.63 kPa by MRE.
  • Statistical analysis included logistic regression to identify independent predictors of MASLD and advanced fibrosis.

Main Results:

  • 52% of overweight individuals had MASLD, and 7% had advanced fibrosis.
  • Hypertriglyceridemia (OR 3.11) and hypertension (OR 2.51) were significant independent predictors of MASLD.
  • Hispanic ethnicity, diabetes, and low HDL were significant predictors of advanced fibrosis. 61% of overweight individuals with MASLD did not have diabetes.

Conclusions:

  • Screening overweight individuals with any CMRF identifies 93.9% of MASLD cases, significantly more than diabetes alone (40.5%).
  • Guidelines should be updated to include overweight individuals with any CMRF for liver fibrosis assessment (e.g., FIB-4).
  • Prioritize fibrosis surveillance in overweight individuals with diabetes and Hispanic ethnicity.